Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Randomized phase II trial evaluating treatment with EGFR-TKI associated with anti-estrogen in women with non-squamous advanced stage NSCLC: IFCT-1003 LADIE trial.

Mazieres J, Barlesi F, Rouquette I, Molinier O, Besse B, Monnet I, Audigier-Valette C, Toffart AC, Renault PA, Fraboulet S, Hiret S, Mennecier B, Debieuvre D, Westeel V, Masson P, Madroszyk-Flandin A, Pichon E, Cortot AB, Amour E, Morin F, Zalcman G, Moro-Sibilot D, Souquet PJ.

Clin Cancer Res. 2020 Mar 6. pii: clincanres.3056.2019. doi: 10.1158/1078-0432.CCR-19-3056. [Epub ahead of print]

PMID:
32144133
2.

Efficacy of Immune Checkpoint Inhibitors in Lung Sarcomatoid Carcinoma.

Domblides C, Leroy K, Monnet I, Mazières J, Barlesi F, Gounant V, Baldacci S, Mennecier B, Toffart AC, Audigier-Valette C, Doucet L, Giroux-Leprieur E, Guisier F, Ricordel C, Molinier O, Perol M, Pichon E, Robinet G, Templement-Grangerat D, Ruppert AM, Rabbe N, Antoine M, Wislez M.

J Thorac Oncol. 2020 Jan 25. pii: S1556-0864(20)30054-X. doi: 10.1016/j.jtho.2020.01.014. [Epub ahead of print]

PMID:
31991225
3.

Phase II Study Evaluating the Mechanisms of Resistance on Tumor Tissue and Liquid Biopsy in Patients With EGFR-mutated Non-pretreated Advanced Lung Cancer Receiving Osimertinib Until and Beyond Radiologic Progression: The MELROSE Trial.

Bennouna J, Girard N, Audigier-Valette C, le Thuaut A, Gervais R, Masson P, Marcq M, Molinier O, Cortot A, Debieuvre D, Cadranel J, Lena H, Moro-Sibilot D, Chouaid C, Mennecier B, Urban T, Sagan C, Perrier L, Barlesi F, Denis MG.

Clin Lung Cancer. 2020 Jan;21(1):e10-e14. doi: 10.1016/j.cllc.2019.09.007. Epub 2019 Oct 1.

PMID:
31648999
4.

Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial.

Moro-Sibilot D, Cozic N, Pérol M, Mazières J, Otto J, Souquet PJ, Bahleda R, Wislez M, Zalcman G, Guibert SD, Barlési F, Mennecier B, Monnet I, Sabatier R, Bota S, Dubos C, Verriele V, Haddad V, Ferretti G, Cortot A, De Fraipont F, Jimenez M, Hoog-Labouret N, Vassal G.

Ann Oncol. 2019 Dec 1;30(12):1985-1991. doi: 10.1093/annonc/mdz407.

PMID:
31584608
5.

Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study).

Descourt R, Perol M, Rousseau-Bussac G, Planchard D, Mennecier B, Wislez M, Cortot A, Guisier F, Galland L, Dô P, Schott R, Dansin E, Arrondeau J, Auliac JB, Chouaid C.

Lung Cancer. 2019 Oct;136:109-114. doi: 10.1016/j.lungcan.2019.08.010. Epub 2019 Aug 14.

PMID:
31491676
6.
7.

Lung resection and immunotherapy: two allied for a new hope in lung cancer cure.

Mennecier B, Olland A, Massard G, Falcoz PE.

J Thorac Dis. 2018 Nov;10(Suppl 33):S4168-S4169. doi: 10.21037/jtd.2018.10.93. No abstract available.

8.

[IoNESCO trial: Immune neoajuvant therapy in early stage non-small cell lung cancer].

Mignard X, Antoine M, Moro-Sibilot D, Dayen C, Mennecier B, Gervais R, Amour E, Milleron B, Morin F, Zalcman G, Wislez M.

Rev Mal Respir. 2018 Nov;35(9):983-988. doi: 10.1016/j.rmr.2018.08.006. Epub 2018 Sep 20. French.

9.

KRAS-specific Amino Acid Substitutions are Associated With Different Responses to Chemotherapy in Advanced Non-small-cell Lung Cancer.

Renaud S, Guerrera F, Seitlinger J, Reeb J, Voegeli AC, Legrain M, Mennecier B, Santelmo N, Falcoz PE, Quoix E, Chenard MP, Weingertner N, Beau-Faller M, Massard G.

Clin Lung Cancer. 2018 Nov;19(6):e919-e931. doi: 10.1016/j.cllc.2018.08.005. Epub 2018 Aug 22.

PMID:
30217639
10.

Systemic Therapy in Advanced Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort.

Merveilleux du Vignaux C, Dansin E, Mhanna L, Greillier L, Pichon E, Kerjouan M, Clément-Duchêne C, Mennecier B, Westeel V, Robert M, Quantin X, Zalcman G, Thiberville L, Lena H, Molina T, Calcagno F, Fournel P, Mazières J, Besse B, Girard N.

J Thorac Oncol. 2018 Nov;13(11):1762-1770. doi: 10.1016/j.jtho.2018.08.005. Epub 2018 Aug 21.

11.

SNAI2 and TWIST1 in lymph node progression in early stages of NSCLC patients.

Emprou C, Le Van Quyen P, Jégu J, Prim N, Weingertner N, Guérin E, Pencreach E, Legrain M, Voegeli AC, Leduc C, Mennecier B, Falcoz PE, Olland A, Santelmo N, Quoix E, Massard G, Guenot D, Chenard MP, Beau-Faller M.

Cancer Med. 2018 May 29. doi: 10.1002/cam4.1545. [Epub ahead of print]

12.

Real-life experience of ceritinib in crizotinib-pretreated ALK+ advanced non-small cell lung cancer patients.

Cadranel J, Cortot AB, Lena H, Mennecier B, Do P, Dansin E, Mazieres J, Chouaid C, Perol M, Barlesi F, Robinet G, Friard S, Thiberville L, Audigier-Valette C, Vergnenegre A, Westeel V, Slimane K, Buturuga A, Moro-Sibilot D, Besse B.

ERJ Open Res. 2018 Feb 13;4(1). pii: 00058-2017. doi: 10.1183/23120541.00058-2017. eCollection 2018 Jan.

13.

Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study.

Duruisseaux M, Besse B, Cadranel J, Pérol M, Mennecier B, Bigay-Game L, Descourt R, Dansin E, Audigier-Valette C, Moreau L, Hureaux J, Veillon R, Otto J, Madroszyk-Flandin A, Cortot A, Guichard F, Boudou-Rouquette P, Langlais A, Missy P, Morin F, Moro-Sibilot D.

Oncotarget. 2017 Mar 28;8(13):21903-21917. doi: 10.18632/oncotarget.15746.

14.

Diagnosis of Jejunal Metastases from Lung Cancer Using Capsule Endoscopy.

Leduc C, Prim N, Mennecier B, Delvaux M, Gangi A, Quoix E.

Case Rep Oncol. 2016 Sep 13;9(3):526-529. eCollection 2016 Sep-Dec.

15.

Gastrointestinal perforations in patients treated with erlotinib: A report of two cases with fatal outcome and literature review.

Gass-Jégu F, Gschwend A, Gairard-Dory AC, Mennecier B, Tebacher-Alt M, Gourieux B, Quoix É.

Lung Cancer. 2016 Sep;99:76-8. doi: 10.1016/j.lungcan.2016.06.012. Epub 2016 Jun 14. Review.

PMID:
27565918
16.

[Prolonged response with paclitaxel after immunotherapy by pembrolizumab in lung cancer].

Zapata E, Mennecier B, Leduc C, Chatron E, Quoix E.

Rev Pneumol Clin. 2016 Oct;72(5):300-304. doi: 10.1016/j.pneumo.2016.05.004. Epub 2016 Aug 22. French.

PMID:
27561974
17.

Successful treatment with ceritinib after crizotinib induced hepatitis.

Sassier M, Mennecier B, Gschwend A, Rein M, Coquerel A, Humbert X, Alexandre J, Fedrizzi S, Gervais R.

Lung Cancer. 2016 May;95:15-6. doi: 10.1016/j.lungcan.2016.02.008. Epub 2016 Feb 23.

PMID:
27040846
18.

Impact of EGFR mutations and KRAS amino acid substitution on the response to radiotherapy for brain metastasis of non-small-cell lung cancer.

Renaud S, Schaeffer M, Voegeli AC, Legrain M, Guérin E, Meyer N, Mennecier B, Quoix E, Falcoz PE, Guénot D, Massard G, Noël G, Beau-Faller M.

Future Oncol. 2016 Jan;12(1):59-70. doi: 10.2217/fon.15.273. Epub 2015 Nov 30.

PMID:
26616848
19.

Correlation between MET protein expression and MET gene copy number in a Caucasian cohort of non-small cell lung cancers according to the new IASLC/ATS/ERS classification.

Weingertner N, Meyer N, Voegeli AC, Guenot D, Renaud S, Massard G, Falcoz PE, Olland A, Mennecier B, Gaub MP, Lindner V, Ghnassia JP, Quoix E, Chenard MP, Beau-Faller M.

Pathology. 2015 Jun;47(4):320-8. doi: 10.1097/PAT.0000000000000269.

PMID:
25938344
20.

Lung Adenocarcinoma with Pulmonary Miliary Metastases and Complex Somatic Heterozygous EGFR Mutation.

Schaller A, Beau-Faller M, Mennecier B, Renaud-Picard B, Weingertner N, Massard G, Quoix E.

Case Rep Oncol. 2014 Nov 19;7(3):769-73. doi: 10.1159/000369526. eCollection 2014 Sep-Dec.

21.

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.

Rizvi NA, Mazières J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, Horn L, Lena H, Minenza E, Mennecier B, Otterson GA, Campos LT, Gandara DR, Levy BP, Nair SG, Zalcman G, Wolf J, Souquet PJ, Baldini E, Cappuzzo F, Chouaid C, Dowlati A, Sanborn R, Lopez-Chavez A, Grohe C, Huber RM, Harbison CT, Baudelet C, Lestini BJ, Ramalingam SS.

Lancet Oncol. 2015 Mar;16(3):257-65. doi: 10.1016/S1470-2045(15)70054-9. Epub 2015 Feb 20.

22.

ALK-rearranged non-small cell lung cancers: how best to optimize the safety of crizotinib in clinical practice?

Girard N, Audigier-Valette C, Cortot AB, Mennecier B, Debieuvre D, Planchard D, Zalcman G, Moro-Sibilot D, Cadranel J, Barlési F.

Expert Rev Anticancer Ther. 2015 Feb;15(2):225-33. doi: 10.1586/14737140.2014.986103. Epub 2014 Nov 21. Review.

PMID:
25413260
23.

Patients with advanced lung cancer harboring oncogenic mutations should be admitted to intensive care units.

Toffart AC, Dhalluin X, Girard N, Chouaid C, Audigier-Valette C, Duruisseaux M, Mennecier B, Parrot A, Fournel P, Moro-Sibilot D, Timsit JF.

Intensive Care Med. 2015 Jan;41(1):164-5. doi: 10.1007/s00134-014-3535-x. Epub 2014 Nov 4. No abstract available.

PMID:
25366122
24.

[ALK-rearranged non-small cell lung cancer: how to optimize treatment with crizotinib in routine practice?].

Audigier-Valette C, Girard N, Cortot AB, Mennecier B, Debieuvre D, Planchard D, Zalcman G, Moro-Sibilot D, Cadranel J, Barlesi F.

Bull Cancer. 2014 Sep;101(9):823-31. doi: 10.1684/bdc.2014.1976. French.

PMID:
25299566
25.

Germ-line exon 21 EGFR mutations, V843I and P848L, in nonsmall cell lung cancer patients.

Prim N, Legrain M, Guerin E, Mennecier B, Weingertner N, Voegeli AC, Guenot D, Maugard CM, Quoix AE, Beau-Faller M.

Eur Respir Rev. 2014 Sep;23(133):390-2. doi: 10.1183/09059180.00009313. No abstract available.

26.

[Afatinib (BIBW 2992)].

Prim N, Fore M, Mennecier B.

Rev Pneumol Clin. 2014 Oct;70(5):279-85. doi: 10.1016/j.pneumo.2014.03.002. Epub 2014 May 27. Review. French.

PMID:
24878189
27.

[Individual lung cancer screening in practice. Perspectives on the propositions from the multidisciplinary group of the Intergroupe francophone de cancérologie thoracique, the Société d'imagerie thoracique and the Groupe d'oncologie de langue française].

Girard N, Gounant V, Mennecier B, Greillier L, Cortot AB, Couraud S, Besse B, Brouchet L, Castelnau O, Ferretti GR, Frappé P, Khalil A, Lefebure P, Laurent F, Liebart S, Margery J, Molinier O, Quoix E, Revel MP, Stach B, Souquet PJ, Thomas P, Trédaniel J, Lemarié E, Zalcman G, Barlési F, Milleron B; groupe de travail multidisciplinaire de l’Intergroupe francophone de cancérologie thoracique, de la Société d’imagerie thoracique et du Groupe d’oncologie de langue française.

Rev Mal Respir. 2014 Jan;31(1):91-103. doi: 10.1016/j.rmr.2013.10.641. Epub 2014 Jan 10. French. No abstract available.

PMID:
24461451
28.

[Hemolytic anemia under erlotinib treatment].

Sakhri L, Mennecier B, Quoix A.

Rev Pneumol Clin. 2013 Dec;69(6):345-50. doi: 10.1016/j.pneumo.2013.06.003. Epub 2013 Oct 31. Review. French.

PMID:
24183296
29.

Second-line therapy in elderly patients with advanced nonsmall cell lung cancer.

Quoix E, Westeel V, Moreau L, Pichon E, Lavolé A, Dauba J, Debieuvre D, Souquet PJ, Bigay-Game L, Dansin E, Poudenx M, Molinier O, Vaylet F, Moro-Sibilot D, Herman D, Sennelart H, Tredaniel J, Mennecier B, Morin F, Baudrin L, Milleron B, Zalcman G; Intergroupe Francophone de Cancérologie Thoracique.

Eur Respir J. 2014 Jan;43(1):240-9. doi: 10.1183/09031936.00048213. Epub 2013 Oct 10.

30.

[Bevacizumab in thoracic oncology: results and practical aspects].

Dansin É, Cousin S, Lauridant G, Mennecier B.

Rev Pneumol Clin. 2013 Jun;69(3):159-69. doi: 10.1016/j.pneumo.2013.02.006. Epub 2013 Apr 15. Review. French.

PMID:
23597632
31.

Impact of 3D conformal radiotherapy on lung function of patients with lung cancer: a prospective study.

Enache I, Noel G, Jeung MY, Meyer N, Oswald-Mammosser M, Pistea C, Jung GM, Mennecier B, Quoix E, Charloux A.

Respiration. 2013;86(2):100-8. doi: 10.1159/000342371. Epub 2012 Nov 13.

32.

From randomized trials to the clinic: is it time to implement individual lung-cancer screening in clinical practice? A multidisciplinary statement from French experts on behalf of the French intergroup (IFCT) and the groupe d'Oncologie de langue francaise (GOLF).

Couraud S, Cortot AB, Greillier L, Gounant V, Mennecier B, Girard N, Besse B, Brouchet L, Castelnau O, Frappé P, Ferretti GR, Guittet L, Khalil A, Lefebure P, Laurent F, Liebart S, Molinier O, Quoix E, Revel MP, Stach B, Souquet PJ, Thomas P, Trédaniel J, Lemarié E, Zalcman G, Barlési F, Milleron B; French lung cancer screening statement taskforce; groupe d'Oncologie de langue française.

Ann Oncol. 2013 Mar;24(3):586-97. doi: 10.1093/annonc/mds476. Epub 2012 Nov 7.

33.

[Atypical metastatic site of lung adenocarcinoma].

Sakhri L, Mennecier B, Jacqmin D, Di Marco A, Schumacher C, Chenard MP, Bergmann E, Quoix E.

Rev Pneumol Clin. 2011 Dec;67(6):375-9. doi: 10.1016/j.pneumo.2011.01.007. Epub 2011 Apr 29. French.

PMID:
22137284
34.

[Muscular metastasis from primary lung cancer: about seven cases].

Hajouji L, Mennecier B, de la Haye Saint-Hilaire D, Bierry G, Canuet M, Quoix E.

Rev Pneumol Clin. 2011 Apr;67(2):75-81. doi: 10.1016/j.pneumo.2010.09.001. Epub 2010 Dec 3. French.

PMID:
21497720
35.

[Metastatic non-small cell lung cancer: Systemic treatment of patients aged 70 and over].

Quoix E, Ducoloné A, Mennecier B, Fraisse P.

Presse Med. 2011 Apr;40(4 Pt 1):420-6. doi: 10.1016/j.lpm.2011.02.008. Epub 2011 Mar 8. Review. French.

PMID:
21388776
36.

[Clinical case No. 1 proposed by the E Quoix (CHRU Strasbourg) team].

Mennecier B, Paumier A, Giroux Leprieur E.

Rev Pneumol Clin. 2010 Apr;66(2 Suppl 1):H3-8. doi: 10.1016/S0761-8417(10)70002-X. French. No abstract available.

PMID:
20488338
37.

[Clinical case No. 4 proposed by the G. Zalcman (CHU Caen) team].

Madelaine J, Mennecier B, Giroux Leprieur E.

Rev Pneumol Clin. 2010 Apr;66(2 Suppl 1):H19-23. doi: 10.1016/S0761-8417(10)70005-5. French. No abstract available.

PMID:
20488337
38.

[Small cell lung cancer and anti-Hu syndrome].

Prim N, Mennecier B, Behr C, Fraisse P, Echaniz-Laguna A, Tranchant C, Quoix E.

Rev Mal Respir. 2010 Mar;27(3):261-5. doi: 10.1016/j.rmr.2010.02.006. Epub 2010 Mar 16. French.

PMID:
20359620
39.

[First-line treatment with pemetrexed in association with cisplatin in patients with non-operable malignant pleural mesothelioma].

Burgin M, Gairard-Dory A-, Mennecier B, Molard A, Beretz L, Quoix A-.

Rev Pneumol Clin. 2009 Apr;65(2):75-83. doi: 10.1016/j.pneumo.2008.12.002. Epub 2009 Apr 1. French.

PMID:
19375046
40.

[Thyroid metastasis of lung cancer and abnormal thyroid function--a case report].

Wirtz G, Quoix E, Grunenberger F, Massard G, Mennecier B.

Rev Pneumol Clin. 2009 Feb;65(1):27-31. doi: 10.1016/j.pneumo.2008.08.003. Epub 2008 Dec 13. French.

PMID:
19306781
41.

EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up.

Ruppert AM, Beau-Faller M, Neuville A, Guerin E, Voegeli AC, Mennecier B, Legrain M, Molard A, Jeung MY, Gaub MP, Oudet P, Quoix E.

Eur Respir J. 2009 Feb;33(2):436-40. doi: 10.1183/09031936.00162307.

42.

A two-faced young woman.

Antoni DN, Jeung MY, Mennecier B, Ruppert AM, Massard G, Quoix E.

J Thorac Oncol. 2009 Feb;4(2):240-1. doi: 10.1097/JTO.0b013e3181949ed1. No abstract available.

43.

Epoetin Beta once-weekly therapy in anemic patients with solid tumors and non-myeloid hematological malignancies receiving chemotherapy.

Spaëth D, Desablens B, Rodon P, Mennecier B, Oudard S, Moullet I, Ghomari K, Bergougnoux L, Bleuzen P, Jenabian A, Ifrah N.

Oncology. 2008;74(1-2):112-8. doi: 10.1159/000139139. Epub 2008 Jun 12.

PMID:
18547966
44.

MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort.

Beau-Faller M, Ruppert AM, Voegeli AC, Neuville A, Meyer N, Guerin E, Legrain M, Mennecier B, Wihlm JM, Massard G, Quoix E, Oudet P, Gaub MP.

J Thorac Oncol. 2008 Apr;3(4):331-9. doi: 10.1097/JTO.0b013e318168d9d4.

45.

[The actual place of anti-angiogenesis in non-small cell lung cancer].

Mennecier B.

Rev Mal Respir. 2007 Oct;24(8 Pt 2):6S198-205. Review. French.

PMID:
18235414
46.

Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer.

Rosell R, Robinet G, Szczesna A, Ramlau R, Constenla M, Mennecier BC, Pfeifer W, O'Byrne KJ, Welte T, Kolb R, Pirker R, Chemaissani A, Perol M, Ranson MR, Ellis PA, Pilz K, Reck M.

Ann Oncol. 2008 Feb;19(2):362-9. Epub 2007 Oct 17.

47.

[Disseminated intravascular coagulation syndrome and thromboembolic complications of non-small-cell lung cancer. A case report].

Sakhri L, Jeung MY, Forher C, Pauli G, Quoix E, Mennecier B.

Rev Pneumol Clin. 2007 Feb;63(1):48-54. French.

PMID:
17457285
48.

[Pituitary metastases from lung cancer. Five cases].

Métivier AC, Mennecier B, Grunenberger F, Schumacher C, Schott R, Jeung MY, Schlienger JL, Pauli G, Quoix E.

Rev Pneumol Clin. 2006 Sep;62(4):231-6. French.

PMID:
17075547
49.

[Lung cancer in elderly patients].

Quoix E, Mennecier B.

Rev Mal Respir. 2005 Dec;22(6 Pt 2):8S63-9. Review. French.

PMID:
16340838
50.

[Lung cancer in women].

Quoix E, Mennecier B.

Rev Mal Respir. 2005 Dec;22(6 Pt 2):8S55-62. Review. French.

PMID:
16340837

Supplemental Content

Loading ...
Support Center